Trials / Completed
CompletedNCT00452504
Single Ascending Dose Study of SRA-444 in Healthy Subjects
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRA-444 Administered Orally to Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a first-in-humans study of SRA-444. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SRA-444 (SR formulation) after administration of ascending single oral doses to healthy adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SRA-444 |
Timeline
- Start date
- 2007-02-01
- Completion
- 2007-06-01
- First posted
- 2007-03-27
- Last updated
- 2007-12-05
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00452504. Inclusion in this directory is not an endorsement.